Clinical Study
A Randomised Controlled Trial of Efficacy of Cognitive Rehabilitation in Multiple Sclerosis: A Cognitive, Behavioural, and MRI Study
Table 1
Baseline demographic characteristics and cognitive performance.
| | | Treatment group () | Control group () | Mean difference (95% CI) | p | | Mean (SD) | Mean (SD) |
| | Age (years) | 46.21 (6.59) | 48.53 (9.63) | −2.31 (−7.75 to 3.12) | 0.588 | | Disease duration (years) | 10.53 (6.13) | 12.68 (9.87) | −2.16 (−7.56 to 3.25) | 0.424 | | EDSS | 4.42 (1.75) | 4.45 (1.77) | −0.26 (−1.18 to 1.13) | 0.964 | | Education (years) | 14.05 (2.76) | 13.63 (2.89) | 0.42 (−1.43 to 2.28) | 0.649 | | SDMT | 43.39 (7.39) | 38.21 (11.39) | 5.18 (−1.27 to 11.63) | 0.112 | | CLVT | 45.32 (9.56) | 43.89 (9.73) | 1.42 (−4.93 to 7.77) | 0.653 | | BVMT | 20.63 (5.77) | 18.05 (7.37) | 2.58 (−1.77 to 6.93) | 0.237 |
| | | N/19 (%) | N/19 (%) | Odds ratio (95% CI) | p |
| | Gender (female) | 13 (68.4) | 14 (73.6) | 0.74 (0.19 to 3.15) | 0.721 | | Unemployed | 13 (68.4) | 11 (57.9) | 1.58 (0.42 to 5.95) | 0.501 | | Disease subtype | | | | | | Relapsing-remitting | 14 (73.6) | 13 (68.4) | 1.29 (0.32 to 5.28) | 0.721 | | Secondary-progressive | 5 (26.3) | 6 (31.6) | | | | On treatment at enrolment | 12 (63.2) | 8 (42.1) | 2.38 (0.64 to 8.68) | 0.194 | | | 5 | 2 | | | | Fingolimod | 5 | 1 | | | | Natalizumab | 2 | 4 | | | | Teriflunomide | 0 | 1 | | |
|
|
Includes Interferon (IF)-1b SC, IF-1A IM and IF-1A SC.
|
